A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1292-1296

  Miles, D W ^a   Towlson, K E ^a   Graham, R ^b   Reddish, M ^c   Longenecker, B M ^c   Taylor Papadimitriou, J ^b   Rubens, R D ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c Biomira Inc   (Canada)

Author keywords

Active specific immunotherapy; Breast; Sialyl Tn

Indexed keywords

CARBOHYDRATE ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; SIALIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHEMA; FEMALE; GRANULOMA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLUENZA; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0029804156     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.532     Document Type: Article

References (18)

1. BERD D AND MASTRANGELO MJ. (1988). Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Inv., 6, 337-349.
2. BERD D, MAGUIRE HC AND MASTRANGELO, MJ. (1984). Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res., 44, 5439-5443.
3. BONAVIDA B, HUTCHINSON IV AND THOMAS AJ. (1979). Cyclophosphamide-sensitive and cyclophosphamide-resistant suppressor cells in the immune response to alloantigens. Transplant Proc., 11, 874-877.
4. FAGERBERG J, HJELM A-L, RAGNHAMMAR P, FRODIN J-E, WIGZELL H AND MELLSTEDT H. (1995). Tumour regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-rcactive T lymphocytes. Cancer Res., 55, 1824-1827.
5. FUNG PYS, MADEJ M, KOGANTY RR AND LONGENECKER BM. (1990). Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res., 50, 4308-4314.
6. GLASER M. (1979). Augmentation of specific immune response against syngeneic SV40 induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell Immunol., 48, 339-345.
7. HAVAS HF AND SCHIFFMAN G. (1991). The effect of cyclophosphamide on the IR of BALB/c mice bearing an IgM plasmacytoma (TEPC-183). Cancer Res., 41, 801-807.
8. HAYWARD JL, CARBONE PP, HEUSON J-C, KUMAOKA S, SEGALOFF A AND RUBENS RD. (1977). Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer, 13, 89-94.
9. ITZKOWITZ SH, BLOOM EJ, KOKAL WA, MODIN G, HAKOMORI S-I AND KIM YS. (1990), Sialosyl Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer, 66, 1960-1989.
10. KOBAYASHI H, TOSHIHIKO T AND KAWASHIMA Y. (1992). Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J. Clin. Oncol., 10, 95-101.
11. NGENECKER BM, REDDISH M, MILES DW AND MACLEAN GD. (1993). Synthetic tumour-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res., 2, 151-162.
12. MACLEAN GD, YACYSHYN-BOWEN MB, SAMUAL J, MEIKLE A, STUART G, NATION J, POPPEMA S, KOGANTY RR, WONG T AND LONGENECKER BM. (1992). Active immunisation of human ovarian cancer patients against a common carcinoma (Thomsen Friedenreich) determinant using a synthetic carbohydrate antigen). J. Immunother., 11, 292-305.
13. MACLEAN GD, REDDISH MA, KOGANTY RR, WONG T, GANDHI S, SMOLENSKI M, SAMUAL J, NABHOLTZ JM AND LONGENECKER JM. (1993). Immunisation of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother., 36, 215-222.
14. MILES DW, HAPPERFIELD LC, SMITH P, GILLIBRAND R, BOBROW LG, GREGORY WM AND RUBENS RD. (1994). Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node positive breast cancer. Br. J. Cancer, 70, 1272-1275.
15. MILES DW, LINEHAN J, SMITH P AND FILIPE I. (1995). Expression of sialyl-Tn in gastric cancer: correlation with known prognostic factors. Br. J. Cancer, 71, 1074-1076.
16. MITCHELL MS, KAN-MITCHELL J, KEMPF RA, HAREL W, SHAU H AND LIND S. (1988). Active specific immunotherapy for melanoma: phase I trial of allogenic lysates and a novel adjuvant. Cancer Res., 48, 5883-5893.
17. ORATZ R, DUGAN M, ROSES DF, HARRIS MN, SPEYER JL, HOCHSTER H, WEISSMAN J, HENN M AND BYSTRYN J-C. (1991). Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Cancer Res., 51, 3643-3647.
18. SINGHAL A, FOHN M AND HAKOMORI S-I. (1991). Induction of α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res., 51, 1406-1411.